Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial
Alexander Poon, Marios Constantinou, Ecosse Lamoureux, Hugh R Taylor
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | WILEY-BLACKWELL | Published : 2008
BACKGROUND: Corneal graft rejection is the commonest cause of graft failure. Currently, intensive topical steroid is the treatment for graft rejection.We hypothesized that the use of topical Cyclosporin A (CsA) 0.05%, specifically Restasis (Allergan) in addition to intensive steroids would aid in the reversal and treatment of endothelial graft rejection. METHODS: In a randomized double masked control study, we recruited 108 patients with acute endothelial graft rejection. They were randomized to two groups. The first group received intensive prednisolone acetate and placebo. The second group received intensive prednisolone acetate and Restasis. RESULTS: There was no difference between the ba..View full abstract
This work was partly supported by Allergan Australia, who supplied the CsA and placebo drops. The authors would like to thank Professor R Vajpayee, Dr G Snibson, Dr M Loughnan, Dr L Sullivan, Dr Mark Daniell, Dr Terrence Ong, Dr Mark Whiting, Dr Ben Connell (Corneal Clinic, Royal Victorian Eye and Ear Hospital, Melbourne, Australia), and all fellows and registrars who participated in the study.